The resulting joint R&D effort is expected to enable US Army Medical Research Institute of Infectious Diseases (USAMRIID) scientists to test the efficacy of AlphaRx’s ‘nanobiotics’ for the treatment of severe intracellular bacterial infections caused by Category A pathogens in animal models. Category A pathogens are organisms classified by US Government used mainly in biological weapons that pose a risk to national security.
The material transfer covers several ‘nanobiotics’ including Ciprofloxacin, Doxycycline and Gentamicin developed by AlphaRx. These are the usual antibiotics used to treat patients in a bioterrorism event.
AlphaRx is excited with the opportunity to work with the US Army. It opens up a non-commercial application to AlphaRx’s drug development programs, with the potential to be a provider to the national stockpile program, through Project Bioshield.